Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly

Sydney B Long, Michael J Blaha, Roger S Blumenthal, Erin D MichosJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USAAbstract: Age is one of the strongest predictors of cardiovascular disease (CVD) risk. Treatment with statins can significantly reduce CVD events and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sydney B Long, Michael J Blaha, Roger S Blumenthal, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	statins elderly rosuvastatin JUPITER primary and secondary cardiovascular prevention Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/25d874b81cfd479a9b2df6b1d957b634
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:25d874b81cfd479a9b2df6b1d957b634
record_format	dspace
spelling	oai:doaj.org-article:25d874b81cfd479a9b2df6b1d957b6342021-12-02T02:44:25ZClinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly1178-1998https://doaj.org/article/25d874b81cfd479a9b2df6b1d957b6342010-12-01T00:00:00Zhttps://www.dovepress.com/clinical-utility-of-rosuvastatin-and-other-statins-for-cardiovascular--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Sydney B Long, Michael J Blaha, Roger S Blumenthal, Erin D MichosJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USAAbstract: Age is one of the strongest predictors of cardiovascular disease (CVD) risk. Treatment with statins can significantly reduce CVD events and mortality in both primary and secondary prevention. Yet despite the high CVD risk among the elderly, there is underutilization of statins in this population (ie, the treatment-risk paradox). Few studies have investigated the use of statins in the elderly, particularly for primary prevention and, as a result, guidelines for treating the elderly are limited. This is likely due to: uncertainties of risk assessment in older individuals where the predictive value of individual risk factors is decreased; the need to balance the benefits of primary prevention with the risks of polypharmacy, health care costs, and adverse medication effects in a population with decreased life expectancy; the complexity of treating patients with many other comorbidities; and increasingly difficult social and economic concerns. As life expectancy increases and the total elderly population grows, these issues become increasingly important. JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) is the largest primary prevention statin trial to date and enrolled a substantial number of elderly adults. Among the 5695 JUPITER participants ≥70 years of age, the absolute CVD risk reduction associated with rosuvastatin was actually greater than for younger participants. The implications of this JUPITER subanalysis and the broader role of statins among older adults is the subject of this review.Keywords: JUPITER, rosuvastatin, elderly, riskSydney B LongMichael J BlahaRoger S Blumenthalet alDove Medical PressarticlestatinselderlyrosuvastatinJUPITERprimary and secondary cardiovascular preventionGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 6, Pp 27-35 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	statins elderly rosuvastatin JUPITER primary and secondary cardiovascular prevention Geriatrics RC952-954.6
spellingShingle	statins elderly rosuvastatin JUPITER primary and secondary cardiovascular prevention Geriatrics RC952-954.6 Sydney B Long Michael J Blaha Roger S Blumenthal et al Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
description	Sydney B Long, Michael J Blaha, Roger S Blumenthal, Erin D MichosJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USAAbstract: Age is one of the strongest predictors of cardiovascular disease (CVD) risk. Treatment with statins can significantly reduce CVD events and mortality in both primary and secondary prevention. Yet despite the high CVD risk among the elderly, there is underutilization of statins in this population (ie, the treatment-risk paradox). Few studies have investigated the use of statins in the elderly, particularly for primary prevention and, as a result, guidelines for treating the elderly are limited. This is likely due to: uncertainties of risk assessment in older individuals where the predictive value of individual risk factors is decreased; the need to balance the benefits of primary prevention with the risks of polypharmacy, health care costs, and adverse medication effects in a population with decreased life expectancy; the complexity of treating patients with many other comorbidities; and increasingly difficult social and economic concerns. As life expectancy increases and the total elderly population grows, these issues become increasingly important. JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) is the largest primary prevention statin trial to date and enrolled a substantial number of elderly adults. Among the 5695 JUPITER participants ≥70 years of age, the absolute CVD risk reduction associated with rosuvastatin was actually greater than for younger participants. The implications of this JUPITER subanalysis and the broader role of statins among older adults is the subject of this review.Keywords: JUPITER, rosuvastatin, elderly, risk
format	article
author	Sydney B Long Michael J Blaha Roger S Blumenthal et al
author_facet	Sydney B Long Michael J Blaha Roger S Blumenthal et al
author_sort	Sydney B Long
title	Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
title_short	Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
title_full	Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
title_fullStr	Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
title_full_unstemmed	Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
title_sort	clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/25d874b81cfd479a9b2df6b1d957b634
work_keys_str_mv	AT sydneyblong clinicalutilityofrosuvastatinandotherstatinsforcardiovascularriskreductionamongtheelderly AT michaeljblaha clinicalutilityofrosuvastatinandotherstatinsforcardiovascularriskreductionamongtheelderly AT rogersblumenthal clinicalutilityofrosuvastatinandotherstatinsforcardiovascularriskreductionamongtheelderly AT etal clinicalutilityofrosuvastatinandotherstatinsforcardiovascularriskreductionamongtheelderly
_version_	1718402149990268928

Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly

Ejemplares similares